Jill E. Sackman, PhD

The Australian pharmaceutical market offers opportunities for manufacturers despite challenges.

Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.

The authors take a look at some of the recent developments in the German pharmaceutical market.

Data analytic strategies can help companies capitalize on personalized medicine.